The DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.
Molnupiravir plus usual care versus usual care alone as early treatment for adults with COVID-19 at increased risk of adverse outcomes (PANORAMIC): an open-label, platform-adaptive randomised controlled trial
Open accessAbstract
BACKGROUND: The safety, effectiveness, and cost-effectiveness of molnupiravir, an oral antiviral medication for SARS-CoV-2, has not been established in vaccinated patients in the community at increased risk of morbidity and mortality from COVID-19. We aimed to establish whether the addition of molnupiravir to usual care reduced hospital admissions and deaths associated with COVID-19 in this population. METHODS: PANORAMIC was a UK-based, national, multicentre, open-label, multigroup, prospective, platform adaptive randomised controlled trial. Eligible participants were aged 50 years or older-or aged 18 years or older with relevant comorbidities-and had been unwell with confirmed COVID-19 for 5 days or fewer in the community. Participants were randomly assigned (1:1) to receive 800 mg molnupiravir twice daily for 5 days plus usual care or usual care only. A secure, web-based system (Spinnaker) was used for randomisation, which was stratified by age (<50 years vs ≥50 years) and vaccination status (yes vs no). COVID-19 outcomes were tracked via a self-completed online daily diary for 28 days after randomisation. The primary outcome was all-cause hospitalisation or death within 28 days of randomisation, which was analysed using Bayesian models in all eligible participants who were randomly assigned. This trial is registered with ISRCTN, number 30448031. FINDINGS: Between Dec 8, 2021, and April 27, 2022, 26 411 participants were randomly assigned, 12 821 to molnupiravir plus usual care, 12 962 to usual care alone, and 628 to other treatment groups (which will be reported separately). 12 529 participants from the molnupiravir plus usual care group, and 12 525 from the usual care group were included in the primary analysis population. The mean age of the population was 56·6 years (SD 12·6), and 24 290 (94%) of 25 708 participants had had at least three doses of a SARS-CoV-2 vaccine. Hospitalisations or deaths were recorded in 105 (1%) of 12 529 participants in the molnupiravir plus usual care group versus 98 (1%) of 12 525 in the usual care group (adjusted odds ratio 1·06 [95% Bayesian credible interval 0·81-1·41]; probability of superiority 0·33). There was no evidence of treatment interaction between subgroups. Serious adverse events were recorded for 50 (0·4%) of 12 774 participants in the molnupiravir plus usual care group and for 45 (0·3%) of 12 934 in the usual care group. None of these events were judged to be related to molnupiravir. INTERPRETATION: Molnupiravir did not reduce the frequency of COVID-19-associated hospitalisations or death among high-risk vaccinated adults in the community. FUNDING: UK National Institute for Health and Care Research.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Molnupiravir for oral treatment of COVID-19 in nonhospitalized patients.
Jayk Bernal, A., Gomes da Silva, M. M., Musungaie, D. B., Kovalchuk, E., Gonzalez, A., Delos Reyes, V., Martín-Quirós, A., Caraco, Y., Williams-Diaz, A., Brown, M. L., et al. (2022) · New England Journal of Medicine · doi:10.1056/nejmoa2116044 · Cited by 1,857
A living WHO guideline on drugs for covid-19 (2020-2023)
Agarwal, A., Hunt, B. J., Stegemann, M., Rochwerg, B., Lamontagne, F., Siemieniuk, R. A., Agoritsas, T., Askie, L., Lytvyn, L., Leo, Y.-S., et al. (2020) · BMJ · doi:10.1136/bmj.m3379 · Cited by 1,041
Master Protocols to Study Multiple Therapies, Multiple Diseases, or Both
Woodcock, J., & LaVange, L. M. (2017) · New England Journal of Medicine · doi:10.1056/nejmra1510062 · Cited by 1,020
Are Racial and Ethnic Minorities Less Willing to Participate in Health Research?
Wendler, D., Kington, R., Madans, J., Wye, G. V., Christ-Schmidt, H., Pratt, L. A., Brawley, O. W., Gross, C. P., & Emanuel, E. (2005) · PLoS Medicine · doi:10.1371/journal.pmed.0030019 · Cited by 854
Drug treatments for covid-19: living systematic review and network meta-analysis
Siemieniuk, R. A., Bartoszko, J. J., Zeraatkar, D., Kum, E., Qasim, A., Díaz Martinez, J. P., Izcovich, A., Rochwerg, B., Lamontagne, F., Han, M. A., et al. (2020) · BMJ · doi:10.1136/bmj.m2980 · Cited by 846
Fischer, W. A., Eron, J. J., Holman, W., Cohen, M. S., Fang, L., Szewczyk, L. J., Sheahan, T. P., Baric, R., Mollan, K. R., Wolfe, C. R., et al. (2022) · Science Translational Medicine · doi:10.1126/scitranslmed.abl7430 · Cited by 529
SARS-CoV-2 infection is effectively treated and prevented by EIDD-2801
Wahl, A., Gralinski, L. E., Johnson, C. E., Yao, W., Kovarova, M., Dinnon, K. H., Liu, H., Madden, V. J., Krzystek, H. M., De, C., et al. (2021) · Nature · doi:10.1038/s41586-021-03312-w · Cited by 409
Painter, W. P., Holman, W., Bush, J. A., Almazedi, F., Malik, H., Eraut, N. C. J. E., Morin, M. J., Szewczyk, L. J., & Painter, G. R. (2021) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.02428-20 · Cited by 397
Cox, R. M., Wolf, J. D., & Plemper, R. K. (2020) · Nature Microbiology · doi:10.1038/s41564-020-00835-2 · Cited by 387
MacPherson, H. (2004) · Complementary Therapies in Medicine · doi:10.1016/j.ctim.2004.07.043 · Cited by 332
Cited by
Therapeutic strategies for COVID-19: progress and lessons learned
Li, G., Hilgenfeld, R., Whitley, R., & De Clercq, E. (2023) · Nature Reviews Drug Discovery · doi:10.1038/s41573-023-00672-y · Cited by 676
Xu, Z., Shi, D., Han, J.-B., Ling, Y., Jiang, X., Lu, X., Li, C., Gong, L., Ge, G., Zhang, Y., et al. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01429-0 · Cited by 301
Metadata
- Authors
- Butler, C. C., Hobbs, F. D. R., Gbinigie, O. A., Rahman, N. M., Hayward, G., Richards, D. B., Dorward, J., Lowe, D. M., Standing, J. F., Breuer, J., Khoo, S., Petrou, S., Hood, K., Nguyen-Van-Tam, J. S., Patel, M. G., Saville, B. R., Marion, J., Ogburn, E., Allen, J., Rutter, H., Francis, N., Thomas, N. P. B., Evans, P., Dobson, M., Madden, T.-A., Holmes, J., Harris, V., Png, M. E., Lown, M., van Hecke, O., Detry, M. A., Saunders, C. T., Fitzgerald, M., Berry, N. S., Mwandigha, L., Galal, U., Mort, S., Jani, B. D., Hart, N. D., Ahmed, H., Butler, D., McKenna, M., Chalk, J., Lavallee, L., Hadley, E., Cureton, L., Benysek, M., Andersson, M., Coates, M., Barrett, S., Bateman, C., Davies, J. C., Raymundo-Wood, I., Ustianowski, A., Carson-Stevens, A., Yu, L.-M., Little, P., Agyeman, A. A., Ahmed, T., Allcock, D., Beltran-Martinez, A., Benedict, O. E., Bird, N., Brennan, L., Brown, J., Burns, G., Butler, M., Cheng, Z., Danson, R., de Kare-Silver, N., Dhasmana, D., Dickson, J., Engamba, S., Fisher, S., Fox, R., Frost, E., Gaunt, R., Ghosh, S., Gilkar, I., Goodman, A., Granier, S., Howell, A., Hussain, I., Hutchinson, S., Imlach, M., Irving, G., Jacobsen, N., Kennard, J., Khan, U., Knox, K., Krasucki, C., Law, T., Lee, R., Lester, N., Lewis, D., Lunn, J., Mackintosh, C. I., Mathukia, M., Moore, P., Morton, S., Murphy, D., Nally, R., Ndukauba, C., Ogundapo, O., Okeke, H., Patel, A., Patel, K., Penfold, R., Poonian, S., Popoola, O., Pora, A., Prasad, V., Prasad, R., Razzaq, O., Richardson, S., Royal, S., Safa, A., Sehdev, S., Sevenoaks, T., Shah, D., Sheikh, A., Short, V., Sidhu, B. S., Singh, I., Soni, Y., Thalasselis, C., Wilson, P., Wingfield, D., Wong, M., Woodall, M. N. J., Wooding, N., Woods, S., Yong, J., Yongblah, F., & Zafar, A.
- Venue
- The Lancet
- Publisher
- Elsevier BV
- Published
- 2023-01
- Volume
- 401
- Issue
- 10373
- Pages
- 281-293
- ISSN
- 0099-5355 (ISSN-L)
- 0140-6736
- OpenAlex
- W4312134853
- Cited by
- 393
- References
- 27
- FWCI
- 41.28
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Molnupiravir plus usual care versus usual care alone as early treatment for adults with COVID-19 at increased risk of adverse outcomes (PANORAMIC): an open-label, platform-adaptive randomised controlled trial. https://app.cochat.ai/papers/10.1016/s0140-6736(22)02597-1
- The paper
- Butler, C. C., Hobbs, F. D. R., Gbinigie, O. A., Rahman, N. M., Hayward, G., Richards, D. B., Dorward, J., Lowe, D. M., Standing, J. F., Breuer, J., Khoo, S., Petrou, S., Hood, K., Nguyen-Van-Tam, J. S., Patel, M. G., Saville, B. R., Marion, J., Ogburn, E., Allen, J., . . . Zafar, A. (2023). Molnupiravir plus usual care versus usual care alone as early treatment for adults with COVID-19 at increased risk of adverse outcomes (PANORAMIC): an open-label, platform-adaptive randomised controlled trial. The Lancet. https://doi.org/10.1016/s0140-6736(22)02597-1
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.